^
Association details:
| Biomarker: | PD-L1 overexpression + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
P78.03 Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC
Published date:
01/12/2021
Excerpt:
Patients with EGFR or ALK alterations who had progressed on at least one approved tyrosine kinase inhibitor and with PD-L1 TPS ≥50% were eligible...Subgroup analysis showed that patients with positive PD-L1 TPS commonly had longer PFS and PFS2 (Table 1).
